CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
CCTG would like to welcome our new Senior Investigator, Dr. James Taylor.
iRECIST training has been a recommended component of immuno-oncology (IO) protocol training documentation in the CCTG Site Training Utility (STU) since 2017. We have recently updated the iRECIST training slides in STU and as of Thursday July 18, 2019, documentation of iRECIST training is now mandatory for Qualified Investigators (QI) participating on new IO trials. In addition to new studies, some recently opened/actively accruing/planned studies will also require documentation of this training for the QI. These trials are: HN9, I227, I238 and I239 (planned).
BRC7 trial has been centrally activated, this is a Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post Progression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker Signature-driven Analysis
Activation Date: July 10, 2019 NCT Registration ID: NCT03793179
CCTG’s Central Operations and Statistics Office is located in the Cancer Research Institute at Queen’s University, with in-house faculty researchers that include clinician scientists, researchers in community health and epidemiology, and biostatisticians. There are currently a number of key potions open on our team - Acting Manager, Office of Clinical Trials Management, Senior Investigator, Study Coordinator, Regulatory Affairs Team Leader, Regulatory Affairs Coordinator, Monitor/Auditor.
There is still time to register for the next CCTG New Investigator Clinical Trials Course (NICTC) being held August 7th to the 9th at the Donald Gordon Centre in Kingston, Ontario.
The NICTC is an important component of the group mandate to provide and facilitate investigator education and training. The major goal of the course is to familiarize new investigators from across the country with the essentials of clinical trial conduct in the Canadian research environment.
Earlier this year Dr. Yee Ung stepped down from his position as the co-chair of the CCTG Lung Disease Site committee. The group convened a selection committee to choose a radiation oncologist as the new co-chair, over several months the committee solicited applications and interviewed several candidates. The members of the selection committee were: Drs. Penny Bradbury, Matthew Parliament, Andrea Bezjak, Yee Ung, and Joe Pater.
A secondary methodological analysis.
Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial
Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated.
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
